Role of bentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma

Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol. 2016;53:186-9.

Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsyproven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124:645-52

Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma - results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534-44.

Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21:2136-40.

Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Stephanie Y, Fox SY, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284-92.

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30:612-20.

LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40-8.

Stamatoullas A, Ghesquieres H, Clement filliatre L, Quittet P, Morschhauser F, Ribrag V, et al. Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134:132.

Cole PD, McCarten K, Metzge KL, Drachtman RA, Horton TM, Pei Q, et al. Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): a Children’s Oncology Group (COG) report. J Clin Oncol. 2017;35:7527.

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853-62.